Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $49.26 USD
Change Today +0.23 / 0.47%
Volume 202.3K
CMRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

chimerix inc (CMRX) Snapshot

Open
$48.36
Previous Close
$49.03
Day High
$50.54
Day Low
$47.73
52 Week High
08/5/15 - $58.04
52 Week Low
09/5/14 - $22.76
Market Cap
2.3B
Average Volume 10 Days
399.5K
EPS TTM
$-2.12
Shares Outstanding
46.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHIMERIX INC (CMRX)

chimerix inc (CMRX) Related Businessweek News

View More BusinessWeek News

chimerix inc (CMRX) Details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds include brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, as well as to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections. Its preclinical testing product includes CMX669 for the treatment of BK virus and CMV. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for certain antiviral indications; and BARDA to develop brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

104 Employees
Last Reported Date: 08/6/15
Founded in 2000

chimerix inc (CMRX) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $419.3K
Chief Commercial Officer
Total Annual Compensation: $333.6K
Chief Medical Officer
Total Annual Compensation: $128.5K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2014.

chimerix inc (CMRX) Key Developments

Chimerix, Inc. Provides Earnings Guidance for the Full Year 2015

Chimerix, Inc. provided earnings guidance for the full year 2015. For the full year 2015, the company expects loss from operations was $25 million for the second quarter of 2015 compared to a loss from operations of $11.6 million for the same period in 2014. The variance was due primarily to the increased research and development and general and administrative expenses.

Chimerix, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Chimerix, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. The company reported a net loss of $24.8 million, or $0.59 per basic and diluted share, for the second quarter of 2015. During the same period in 2014, the company recorded a net loss of $11.7 million, or $0.39 per basic and diluted share. Revenues for the second quarter of 2015 increased to $4.1 million compared to $0.9 million for the same period in 2014, due to an increase in the second quarter of 2015 in reimbursable expenses associated with the company's ongoing development contract with Biomedical Advanced Research and Development Authority (BARDA), and the recognition of deferred revenue related to the company's collaboration and licensing agreement with ContraVir Pharmaceuticals. Loss from operations was $25.0 million for the second quarter of 2015, compared to a loss from operations of $11.6 million for the same period in 2014. The variance was primarily due to the increased research and development, and general and administrative expenses. For the six months, the company reported net loss of $47.080 million or $1.13 per diluted share on total revenue of $5.381 million compared to net loss of $22.134 million or $0.78 per diluted share on total revenue of $1.699 million reported in the same period last year. Loss from operations was $42.279 million against $21.780 million reported last year.

Chimerix, Inc. Completes Targeted Enrollment for Brincidofovir Phase 3 Advise Trial for Adenovirus Infection

Chimerix, Inc. announced completion of enrollment of the targeted 200 patients in the Phase 3 AdVise trial evaluating brincidofovir for the treatment of adenovirus infection in immunocompromised patients. Adenovirus is a common virus that leads to upper respiratory or gastrointestinal infections in individuals with a healthy immune system, but it can be rapidly fatal in individuals with a weakened immune system, particularly those who have recently undergone a hematopoietic cell transplant (HCT), or bone marrow transplant. There is no approved antiviral treatment for adenovirus infection.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMRX:US $49.26 USD +0.23

CMRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Achillion Pharmaceuticals Inc $7.74 USD +0.19
Bavarian Nordic A/S kr292.50 DKK -2.00
Bioporto A/S kr2.87 DKK -0.07
Emergent BioSolutions Inc $32.49 USD -0.17
PharmAthene Inc $1.47 USD +0.03
View Industry Companies
 

Industry Analysis

CMRX

Industry Average

Valuation CMRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 267.2x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 258.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIMERIX INC, please visit www.chimerix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.